Phase 2 N=78 Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss
Age-Related Hearing Loss
Primary: Change in Hearing Loss After 4 Weeks of Treatment — -1.114; -1.914 decibels (dB)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=608 A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 12 — 25.1; 27.6; 27.2 Percentage of participants — p=0.546
Phase 3 N=106 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Time to First Confirmed Worsening on the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale — 721.0; 540.0 Days — p=0.9838
Phase 3 N=485 A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Non-Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 11.86; 10.22 Months — p=0.1044
Phase 2 N=70 Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Type 1 Diabetes
Primary: 2 Hour C-peptide AUC in Response to MMTT — 358; 495 pmol/L — p=0.81
N/A N=286 Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM
Methamphetamine Abuse · HIV
Primary: Methamphetamine Use — 11.13; 10.75; 10.34; 7.79 Days Used in the Past 30 Days — p=0.3137
N/A N=55 Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Meibomian Gland Dysfunction · Dry Eye
Primary: Mean Change in Meibomian Gland Score From Baseline at 3 Months — 12.4; 1.4 units on a scale — p=<0.0001
Phase 3 N=135 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Carcinoid Syndrome
Primary: Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks — -0.623; -1.433; -1.455 counts/day — p=< 0.001
Phase 2 N=139 Exercise and Metformin in Colorectal and Breast Cancer Survivors
Colorectal Cancer · Breast Cancer
Primary: Change in Fasting Insulin Level — -2.47; -0.08; -1.16; 2.79 mU/L — p=<0.0001
Phase 3 N=60 Black Widow Spider Antivenin for Patients With Systemic Latrodectism
Latrodectism
Primary: Number of Participants With Treatment Failure — 15; 24 Participants — p=0.0185
Phase 3 N=71 Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants
Pain, Postoperative
Primary: Assessment Of Participant's Ability To Use The SSEC — 1; 2; 10; 48 participants
N/A N=14 Initial Efficacy Study of Supporting Play, Exploration, & Early Development Intervention
Infant, Premature, Diseases · Brain White Matter Disease Periventricular
Primary: Reaching (Toy Contact Duration) — 20.2; 28.02 Seconds
Phase 4 N=20 Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness
Tooth Loss · Peri-implant Mucosa Defect
Primary: Change in Buccal Peri-implant Mucosa Thickness Between Baseline and 16 Weeks After Surgery — 0.44; 0.05 millimeters
Phase 2 N=14 Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
Keratosis, Actinic
Primary: Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA — 39.05 ng/mL
Phase 2 N=19 Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP) — -254.96; -564.27; 3.13; -397.72 ng/mL — p=0.0285